ANCN vs. IMRX, OPTN, KRON, UNCY, ALXO, LTRN, PDSB, IMMX, STTK, and RPTX
Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Immuneering (IMRX), OptiNose (OPTN), Kronos Bio (KRON), Unicycive Therapeutics (UNCY), ALX Oncology (ALXO), Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Shattuck Labs (STTK), and Repare Therapeutics (RPTX). These companies are all part of the "medical" sector.
Anchiano Therapeutics vs.
Immuneering (NASDAQ:IMRX) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.
In the previous week, Immuneering had 1 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 1 mentions for Immuneering and 0 mentions for Anchiano Therapeutics. Immuneering's average media sentiment score of 0.00 equaled Anchiano Therapeutics'average media sentiment score.
Immuneering has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
67.7% of Immuneering shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 25.0% of Immuneering shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Anchiano Therapeutics received 25 more outperform votes than Immuneering when rated by MarketBeat users. However, 67.35% of users gave Immuneering an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote.
Anchiano Therapeutics has lower revenue, but higher earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.
Anchiano Therapeutics' return on equity of 36.08% beat Immuneering's return on equity.
Immuneering presently has a consensus price target of $12.20, suggesting a potential upside of 575.90%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Anchiano Therapeutics.
Summary
Immuneering beats Anchiano Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Anchiano Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anchiano Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ANCN) was last updated on 2/22/2025 by MarketBeat.com Staff
